当前位置： SCI文献检索 > VACCINE期刊下所有文献 > Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.

Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.

Abstract：

BACKGROUND:Each year a substantial number of Dutch elderly suffers from herpes zoster (HZ), caused by the reactivation of the varicella zoster virus (VZV). A potential complication of HZ is postherpetic neuralgia (PHN) which results in a prolonged loss of quality of life. A large randomized clinical trial, labelled the Shingles Prevention study (SPS), demonstrated that a live attenuated VZV vaccine can reduce the incidence of HZ and PHN. OBJECTIVE:We aimed to estimate the incremental cost-effectiveness ratio (ICER) of vaccination of the elderly against HZ versus no such vaccination in The Netherlands. METHODS:A cohort model was developed to compare the costs and effects in a vaccinated and a non-vaccinated age- and gender-stratified cohort of immune-competent elderly. Vaccination age was varied from 60 to 75 years. Data from published literature such as the SPS were used for transition probabilities. The study was performed from the societal as well as the health care payer's perspective and results were expressed in euros per quality-adjusted life year (QALY) gained. RESULTS:In the base case, we estimated that vaccination of a cohort of 100,000 60-year-olds would prevent 4136 cases of HZ, 305 cases of PHN resulting in a QALY-gain of 209. From the societal perspective, a total of €1.9 million was saved and the ICER was €35,555 per QALY gained when a vaccine price of €87 was used. Vaccination of women resulted in a lower ICER than vaccination of men (€33,258 vs. €40,984 per QALY gained). The vaccination age with the most favourable ICER was 70 years (€29,664 per QALY gained). Parameters with a major impact on the ICER were the vaccine price and HZ incidence rates. In addition, the model was sensitive to utility of mild pain, vaccine efficacy at the moment of uptake and the duration of protection induced by the vaccine. CONCLUSION:Vaccination against HZ might be cost-effective for ages ranging from 60 to 75 when a threshold of €50,000 per QALY gained would be used, at €20,000 per QALY this might not be the case. Additional information on the duration of vaccine-protection is needed to further optimize cost-effectiveness estimations.

journal_name

Vaccine

journal_title

Vaccine

authors

de Boer PT,Pouwels KB,Cox JM,Hak E,Wilschut JC,Postma MJ

doi

10.1016/j.vaccine.2012.12.067

subject

Has Abstract

pub_date

2013-02-18 00:00:00

pages

1276-83

issue

9

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(12)01854-3

journal_volume

31

pub_type

杂志文章

相关文献

VACCINE文献大全
  • An alternative signal 3: CD8⁺ T cell memory independent of IL-12 and type I IFN is dependent on CD27/OX40 signaling.

    abstract：:Type I IFN and IL-12 are well documented to serve as so called "signal 3" cytokines, capable of facilitating CD8(+) T cell proliferation, effector function and memory formation. While their ability to serve in this capacity is well established, to date, no non-cytokine signal 3 mediators have been clearly identified. ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2011.12.017

    authors： Sanchez PJ,Kedl RM

    更新日期：2012-02-01 00:00:00

  • Immunization with DnaJ (hsp40) could elicit protection against nasopharyngeal colonization and invasive infection caused by different strains of Streptococcus pneumoniae.

    abstract：:Increasing mortality, morbidity and economic costs have been paid to pneumococcal diseases every year. Currently, vaccination is the most promising strategy to reduce the occurrence of pneumococcal infection. In this study, we investigated the protective efficacy of immunization with recombinant DnaJ (hsp40) protein a...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2010.12.126

    authors： Cui Y,Zhang X,Gong Y,Niu S,Yin N,Yao R,Xu W,Li D,Wang H,He Y,Cao J,Yin Y

    更新日期：2011-02-17 00:00:00

  • Pandemic whole-virion, Vero-cell-derived, adjuvant-free influenza A H1N1 vaccine in patients with solid tumors and hematologic malignancies receiving concurrent anticancer treatment: Immunogenicity, tolerability, and acceptability during the pandemic situ

    abstract：:Patients with malignancies are considered to be at increased risk of acquiring influenza. Because of higher complication and case fatality rates, preventive measures such as vaccination are of great interest. The objective of this study was to assess the acceptability, tolerability and immunogenicity of an adjuvant-fr...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2012.09.005

    authors： Lagler H,Tobudic S,Ramharter M,Elandt K,Sperr WR,Redlberger-Fritz M,Popow-Kraupp T,Jäger U,Zielinski CC,Burgmann H

    更新日期：2012-11-06 00:00:00

  • Developing an HPV vaccine to prevent cervical cancer and genital warts.

    abstract：:The challenges of the journey from target identification through development of a prophylactic quadrivalent human papillomavirus (HPV) vaccine have been met in Gardasil. Cervical cancer is the second leading cause of cancer-related death in women worldwide. Approximately 70% of cervical cancer is caused by infection w...

    journal_title：Vaccine

    pub_type： 杂志文章,评审

    doi：10.1016/j.vaccine.2007.01.013

    authors： Bryan JT

    更新日期：2007-04-20 00:00:00

  • Vaccination against the 2009 pandemic influenza A (H1N1) among healthcare workers in the major teaching hospital of Sicily (Italy).

    abstract：:The aim of the study was to investigate factors involved in vaccination acceptance among healthcare workers (HCWs) and adverse reactions rates associated with pandemic influenza vaccination. The study was carried out in the major teaching hospital of Sicily from November 2009 to February 2010 on 2267 HCWs. A total of ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2010.12.041

    authors： Amodio E,Anastasi G,Marsala MG,Torregrossa MV,Romano N,Firenze A

    更新日期：2011-02-04 00:00:00

  • Immunization with an engineered mutant trans-sialidase highly protects mice from experimental Trypanosoma cruzi infection: a vaccine candidate.

    abstract：:Chagas' disease is a major tropical disease for which a cure for chronic phase does not exist yet. Trypanosoma cruzi trans-sialidase (TS) seems to be involved in relevant processes such as infectivity, host survival and, very importantly, disease pathogenesis. In this study, we show that mice vaccinated with an engine...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2008.02.060

    authors： Fontanella GH,De Vusser K,Laroy W,Daurelio L,Nocito AL,Revelli S,Contreras R

    更新日期：2008-05-02 00:00:00

  • Delivering the promise of the Decade of Vaccines: opportunities and challenges in the development of high quality new vaccines.

    abstract：:The Decade of Vaccines (DoV) initiative, launched in 2010, has as its mission "to extend, by 2020 and beyond, the full benefits of immunization to all people, regardless of where they are born, who they are, or where they live". Through their life-saving vaccines, the research-based vaccine companies represented by th...

    journal_title：Vaccine

    pub_type： 杂志文章,评审

    doi：10.1016/j.vaccine.2012.12.032

    authors： Keith JA,Agostini Bigger L,Arthur PA,Maes E,Daems R

    更新日期：2013-04-18 00:00:00

  • Identification by genomic immunization of a pool of DNA vaccine candidates that confer protective immunity in mice against Neisseria meningitidis serogroup B.

    abstract：:We have shown previously that expression library immunization is viable alternative approach to induce protective immunity against Neisseria meningitidis serogroup B. In this study we report that few rounds of library screening allow identification of protective pools of defined antigens. A previously reported protect...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2007.04.084

    authors： Yero D,Pajón R,Pérez Y,Fariñas M,Cobas K,Diaz D,Solis RL,Acosta A,Brookes C,Taylor S,Gorringe A

    更新日期：2007-07-09 00:00:00

  • Immunization with DNA, adenovirus or both in biodegradable alginate microspheres: effect of route of inoculation on immune response.

    abstract：:To determine the potential for biodegradable alginate microspheres to be used as a delivery vehicle for DNA based vaccines, we constructed a plasmid, pMNe-gal-SV40, containing the bacterial beta-galactosidase (LacZ) gene under the control of the murine cytomegalovirus (MCMV) immediate-early promoter and the simian vir...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(00)00170-5

    authors： Mittal SK,Aggarwal N,Sailaja G,van Olphen A,HogenEsch H,North A,Hays J,Moffatt S

    更新日期：2000-09-15 00:00:00

  • Feasibility study of a combined diphtheria-tetanus-acellular pertussis-hepatitis B (DTPa-HBV) vaccine, and comparison of clinical reactions and immune responses with diphtheria-tetanus-acellular pertussis (DTPa) and hepatitis B vaccines applied as mixed o

    abstract：:The feasibility of a combined diphtheria-tetanus-acellular pertussis-hepatitis B (DTPa-HBV) vaccine was assessed and a comparison made of immunogenicity and reactogenicity to DTPa and HBV vaccines mixed in one syringe and to concomitant but separate injections as a primary vaccination course in three groups of infants...

    journal_title：Vaccine

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1016/s0264-410x(97)00089-3

    authors： Usonis V,Bakasenas V,Willems P,Clemens R

    更新日期：1997-10-01 00:00:00

  • Hepatitis B specific T cell immunity induced by primary vaccination persists independently of the protective serum antibody level.

    abstract：:In 2005, in accordance with recommendations made by the European Medicines Agency, the Italian Drug Agency ordered withdrawal of the hexavalent Hexavac(®) vaccine (Sanofi Pasteur MSD) from the market. Concerns had been raised about the low immunogenicity of the hepatitis B virus component of the vaccine, assessed by m...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2012.11.029

    authors： Carollo M,Palazzo R,Bianco M,Pandolfi E,Chionne P,Fedele G,Tozzi AE,Carsetti R,Romanò L,Ausiello CM

    更新日期：2013-01-07 00:00:00

  • Poor knowledge of vaccination recommendations and negative attitudes towards vaccinations are independently associated with poor vaccination uptake among adults - Findings of a population-based panel study in Lower Saxony, Germany.

    abstract：OBJECTIVES:The aims of this study were to (a) assess knowledge of official vaccination recommendations and attitudes towards vaccinations among adults and (b) examine their association with vaccination uptake among adults. METHODS:This study was part of the HaBIDS study (Hygiene and Behaviour Infectious Diseases Surve...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2018.03.050

    authors： Akmatov MK,Rübsamen N,Deyneko IV,Karch A,Mikolajczyk RT

    更新日期：2018-04-25 00:00:00

  • The epidemiology of hepatitis B virus infection in HIV-infected and HIV-uninfected pregnant women in the Western Cape, South Africa.

    abstract：OBJECTIVES:Persistent hepatitis B virus (HBV) infection is a major cause of morbidity and mortality in sub-Saharan Africa. The HIV epidemic has the potential to affect its biology. Immunisation protocols established in the pre-HIV era are based upon data showing predominantly horizontal infant transmission. This study ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2013.08.028

    authors： Andersson MI,Maponga TG,Ijaz S,Barnes J,Theron GB,Meredith SA,Preiser W,Tedder RS

    更新日期：2013-11-12 00:00:00

  • Use of fusion protein constructs to generate potent immunotherapy and protection against scorpion toxins.

    abstract：:We report the use of recombinant scorpion toxins in the form of fusion proteins as antigens for immunisation in rabbits and mice: the aim was to produce in these animal models protective antisera against the most lethal alpha-type toxins in the venom from the North African scorpion Androctonus australis. The cDNAs enc...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(01)00379-6

    authors： Legros C,Kaabi H,El Ayeb M,Céard B,Vacher H,Bougis PE,Martin-Eauclaire MF

    更新日期：2001-12-12 00:00:00

  • Identification of population at risk for future Clostridium difficile infection following hospital discharge to be targeted for vaccine trials.

    abstract：BACKGROUND:Efforts to develop a Clostridium difficile vaccine are underway; identification of patients at risk for C. difficile infection (CDI) is critical to inform vaccine trials. We identified groups at high risk of CDI ≥ 2 8 days after hospital discharge. METHODS:Hospital discharge data and pharmacy data from two ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2015.09.078

    authors： Baggs J,Yousey-Hindes K,Ashley ED,Meek J,Dumyati G,Cohen J,Wise ME,McDonald LC,Lessa FC

    更新日期：2015-11-17 00:00:00

  • Structural perturbation of diphtheria toxoid upon adsorption to aluminium hydroxide adjuvant.

    abstract：:Aluminium-containing adjuvants are often used to enhance the potency of vaccines. In the present work we studied whether adsorption of diphtheria toxoid to colloidal aluminium hydroxide induces conformational changes of the antigen. Diphtheria toxoid has a high affinity for the aluminium hydroxide particles based on a...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2012.09.020

    authors： Régnier M,Metz B,Tilstra W,Hendriksen C,Jiskoot W,Norde W,Kersten G

    更新日期：2012-11-06 00:00:00

  • Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age.

    abstract：BACKGROUND:Alternative methods for influenza vaccine production are needed to ensure adequate supplies. METHODS:Healthy adults 50-64 years were assigned randomly to receive one intramuscular injection of trivalent recombinant hemagglutinin (rHA) or U.S. licensed trivalent inactivated vaccine (TIV) containing H1, H3 an...

    journal_title：Vaccine

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1016/j.vaccine.2011.01.039

    authors： Baxter R,Patriarca PA,Ensor K,Izikson R,Goldenthal KL,Cox MM

    更新日期：2011-03-09 00:00:00

  • Fish soluble Toll-like receptor (TLR)5 amplifies human TLR5 response via physical binding to flagellin.

    abstract：:Fish has a soluble form of TLR5 ortholog (TLR5S), which does not exist in mammals. We identified TLR5S from rainbow trout and named rtTLR5S, which was about 38% homologous to the extracellular domains of human (hu) and mouse TLR5. Adjuvancy of rtTLR5S to flagellin response by human TLR5 (huTLR5) was tested in this stu...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2005.11.003

    authors： Tsujita T,Ishii A,Tsukada H,Matsumoto M,Che FS,Seya T

    更新日期：2006-03-15 00:00:00

  • Successful DNA immunisation of rats against fasciolosis.

    abstract：:The liver fluke Fasciola hepatica contributes to great economic and health losses in the cattle industry in many countries, including Poland. Unfortunately, no vaccine against fasciolosis is commercially available. We have designed a DNA vaccine and tested it in rats. Groups of male or female rats received one intramu...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(00)00095-5

    authors： Kofta W,Mieszczanek J,Płucienniczak G,Wedrychowicz H

    更新日期：2000-07-01 00:00:00

  • The suitability of yellow fever and Japanese encephalitis vaccines for immunization against West Nile virus.

    abstract：:Seven volunteers involved in flavivirus studies have been immunized with commercial Japanese encephalitis and yellow fever vaccines JE-VAX and YF-VAX. Strong homologous and cross-reactive with West Nile virus (WNV) antibody responses with titers 1:1600 to 1:51200 were found in all donors. All donors developed high lev...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2005.04.036

    authors： Yamshchikov G,Borisevich V,Kwok CW,Nistler R,Kohlmeier J,Seregin A,Chaporgina E,Benedict S,Yamshchikov V

    更新日期：2005-09-15 00:00:00

  • Infant vaccination timing: Beyond traditional coverage metrics for maximizing impact of vaccine programs, an example from southern Nepal.

    abstract：BACKGROUND:Immunization programs currently measure coverage by assessing the proportion of children 12-24 months who have been immunized but this does not address the important question of when the scheduled vaccines were administered. Data capturing the timing of vaccination in first 6 months, when severe disease is m...

    journal_title：Vaccine

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.vaccine.2015.12.061

    authors： Hughes MM,Katz J,Englund JA,Khatry SK,Shrestha L,LeClerq SC,Steinhoff M,Tielsch JM

    更新日期：2016-02-10 00:00:00

  • The history of the United States Advisory Committee on Immunization Practices (ACIP).

    abstract：:The United States Advisory Committee on Immunization Practices (ACIP) is a federal advisory committee that develops written recommendations for use of vaccines licensed by the Food and Drug Administration (FDA) for the U.S. civilian population. Vaccine development and disease outbreaks contributed to the need for a sy...

    journal_title：Vaccine

    pub_type： 历史文章,杂志文章

    doi：10.1016/j.vaccine.2014.09.043

    authors： Walton LR,Orenstein WA,Pickering LK

    更新日期：2015-01-09 00:00:00

  • Towards developing standardized protocols for evaluation of cellular mucosal immune responses - Recommendations from a DAIDS/NIH workshop, June 15-16, 2009.

    abstract：:Although 80% of HIV infections occur through mucosal routes and vaccine strategies need to be designed for inducing protective immune responses at the site of the viral entry, it has proven to be very challenging to measure these responses. A 2-day workshop was convened by Division of AIDS, National Institutes of Heal...

    journal_title：Vaccine

    pub_type：

    doi：10.1016/j.vaccine.2010.04.092

    authors： Mehra V,Musib R,Schito ML

    更新日期：2010-07-05 00:00:00

  • Cost-benefit evaluation of influenza vaccination in the elderly in the Italian region of Liguria.

    abstract：:Influenza causes considerable morbidity and mortality and the damage to public health can be considerable. The most effective measures available for the prevention of influenza is vaccination. In most industrialised countries the objective of vaccination is to limit the disease among individuals at risk, especially th...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(02)00507-8

    authors： Gasparini R,Lucioni C,Lai P,Maggioni P,Sticchi L,Durando P,Morelli P,Comino I,Calderisi S,Crovari P

    更新日期：2002-12-20 00:00:00

  • Alterations in serotype-specific B cell responses to the 13-valent pneumococcal conjugate vaccine in aging HIV-infected adults.

    abstract：BACKGROUND:Advanced age and human immunodeficiency virus (HIV) infection are associated with increased pneumococcal disease risk. The impact of these factors on cellular responses to vaccination is unknown. METHODS:HIV-infected (HIV+) individuals 50-65 years old with CD4(+) Tcells/μl (CD4) >200 on antiretroviral thera...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2015.12.013

    authors： Ohtola JA,Khaskhely NM,Saul-Mcbeth JL,Iyer AS,Leggat DJ,Khuder SA,Westerink MAJ

    更新日期：2016-01-20 00:00:00

  • Efficacious, nontoxigenic Bacillus anthracis spore vaccines based on strains expressing mutant variants of lethal toxin components.

    abstract：:We reported previously on the development of a Bacillus anthracis vaccine strain expressing high levels of recombinant protective antigen (rPA) [Cohen et al., Infec Immun 2000;68(8):4549-58]. To further explore the potential of the B. anthracis platform, we generated several attenuated strains expressing lethal toxin ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2004.11.077

    authors： Mendelson I,Gat O,Aloni-Grinstein R,Altboum Z,Inbar I,Kronman C,Bar-Haim E,Cohen S,Velan B,Shafferman A

    更新日期：2005-12-01 00:00:00

  • Past, present and future of HIV vaccine trials in developing countries.

    abstract：:A safe, effective and accessible preventive vaccine is our best long-term hope for the control of the HIV/AIDS pandemic. The first phase I trial of an HIV vaccine was conducted in the US in 1987. Since then, >30 candidate vaccines have been tested in over 60 phase I/II clinical trials, involving >8000 healthy human vo...

    journal_title：Vaccine

    pub_type： 杂志文章,评审

    doi：10.1016/s0264-410x(02)00062-2

    authors： Esparza J,Osmanov S,Pattou-Markovic C,Touré C,Chang ML,Nixon S

    更新日期：2002-05-06 00:00:00

  • Midwife attitudes: an important determinant of maternal postpartum pertussis booster vaccination.

    abstract：BACKGROUND:The study was designed to determine the feasibility of implementing routine dTpa vaccination in the maternity ward to new mothers and to assess midwives' attitudes toward pertussis booster vaccination, their perceived susceptibility and severity of pertussis in their patients' communities, the perceived barr...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2011.05.049

    authors： Robbins SC,Leask J,Hayles EH,Sinn JK

    更新日期：2011-08-05 00:00:00

  • An ESAT-6:CFP10 DNA vaccine administered in conjunction with Mycobacterium bovis BCG confers protection to cattle challenged with virulent M. bovis.

    abstract：:The potency of genetic immunization observed in the mouse has demonstrated the utility of DNA vaccines to induce cell-mediated and humoral immune responses. However, it has been relatively difficult to generate comparable responses in non-rodent species. The use of molecular adjuvants may increase the magnitude of the...

    journal_title：Vaccine

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.vaccine.2007.03.052

    authors： Maue AC,Waters WR,Palmer MV,Nonnecke BJ,Minion FC,Brown WC,Norimine J,Foote MR,Scherer CF,Estes DM

    更新日期：2007-06-11 00:00:00

  • Heritability of vaccine-induced measles neutralizing antibody titers.

    abstract：:Understanding how genetics influences inter-individual variation of antibody titers in response to measles vaccination is vital to understanding possible sources of vaccine failure as well as improved vaccine development. Although it is recognized that both the human leukocyte antigen (HLA) genes and the immunoglobuli...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2017.01.078

    authors： Schaid DJ,Haralambieva IH,Larrabee BR,Ovsyannikova IG,Kennedy RB,Poland GA

    更新日期：2017-03-07 00:00:00